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INTRODUCTION 
 
Incidence of malignancies is on the rise. Advances in treatment protocols 
have resulted in increased longevity of the patients. Therefore greater focus is 
now on comorbid conditions, treatment of which would improve the survival and 
quality of life. 
Over the past decade, there has been a growing appreciation of anaemia 
as the source of a wide range of symptoms and poorer outcomes in cancer 
patients.  
Data published on 15 September, 2004 in the European Journal of 
Cancer1 (online edition) reveals two out of three cancer patients suffer from 
anaemia  and only  40% of these patients receive appropriate treatment 
(anaemia defined as haemoglobin less than 12 g/dL). Low haemoglobin levels 
correlate with poor quality of life and physical performance. Performance status 
deteriorates with decreasing haemoglobin. This correlation remains regardless of 
disease status or cancer treatment. 
J Jaime  Caro et al2, in their systematic and quantitative review of anaemia 
as an independent prognostic factor for survival in patients with cancer, found 
that anaemia was associated with shorter survival times for patients with lung 
carcinoma, cervicouterine carcinoma, head and neck cancer, prostatic 
carcinoma, lymphoma and multiple myeloma. The overall estimated increase in 
risk of death was 65% (54 – 77%). 
Tumour hypoxia may directly contribute to the resistance of the cancer 
patient to radiation therapy or chemotherapy via deprivation of the oxygen 
essential for the cytotoxic actions of these agents. Indirectly, tumour hypoxia may 
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contribute to radioresistance and chemoresistance by inducing proteomic and 
genomic changes that lead ultimately to malignant progression, with reduced 
local control and metastatic spread, and ultimately, increased resistance and 
decreased survival time. A direct association between hypoxia and anaemia 
appears likely, and anaemia is a modifiable condition in many cancer patients. 
This being the case, reducing tumour hypoxia by correcting anaemia with 
recombinant human erythropoietin (rHuEPO) and other agents  appears to offer 
one possible therapeutic option for enhancing the effectiveness of standard 
cancer therapies3.   Hence, it is worthwhile to study the incidence and pattern of 
anaemia in cancer patients in our hospital and create a database so that   timely 
intervention by the oncologists with strategies to improve the outcome of 
treatment can be instituted whenever anaemia is diagnosed.  
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AIMS AND OBJECTIVES 
 
 
The present study is undertaken 
 
1) To study the incidence and pattern of  anaemia in nonhaematological 
malignancies in patients aged 19 – 69 years attending an urban referral hospital 
2 ) To study the severity of anaemia based on the haemoglobin concentration 
and 
3) To study the haematological parameters in solid malignancies. 
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REVIEW OF LITERATURE 
 
 
Haematopoiesis, the normal process of blood cell development, is 
dependent on the smooth functioning of three factors4 : 1) the continuing 
presence of stem cells that are capable of differentiating and developing into 
mature blood cells 2) a bone marrow environment that is supportive of stem cell 
survival and functioning and 3) a complex system of highly regulated 
haematopoietic growth factors that regulate the  proliferation, differentiation and 
survival of blood cells. Anaemia results when this system fails to function 
properly. 
PREVALENCE OF ANAEMIA IN CANCER PATIENTS 
Anaemia is a common accompaniment of malignancy. The prevalence of 
anaemia due to cancer progression varies based on the definition of anaemia 
and the type of cancer involved. 
A survey of 38 studies, most of which evaluated anaemia prevalence in 
cancer patients before treatment found that the prevalence ranged from 5% 
(prostate cancer) to as high as 90% (multiple myeloma).The prevalence of 
anaemia appears to be especially high in patients with uterine-cervical cancers, 
advanced multiple myeloma and those suffering from cancer- related renal 
impairment5 . 
In a study at Beth Israel Medical Center and St. Luke’s-Roosevelt Hospital 
Center, USA, 48% of patients presented to the Radiation Oncology department 
with anaemia (Hb <12 g/dL) and a total of 57% ultimately became anaemic by 
the end of the therapy6. 
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15th Data published in the European Journal of Cancer (online edition) 
dated September 2004 reveals the following: 
(Anaemia defined as Hb <12 g/dL)                                                               
                             
                                      
Table 1. The burden of anaemia                                                                 
(from the European Cancer Anaemia Survey) 
 
Treatment Status 
 
Haematological 
Tumours        
(n = 3010) 
 
 
Solid tumours       
(n =11,453) 
 
Prior to treatment 
initiation               
 
48% 
 
28% 
 
 
During treatment   
 
72% 
 
66% 
 
 
Number of patients 
untreated for Hb less 
than 10 g/dL 
 
 
51% 
 
63% 
 
  (Ludwig and colleagues)7 
 
A number of different factors can contribute to anaemia in 
nonhaematological malignancy and it is common for several factors to operate in 
patients with malignancy. The type of anaemia depends on the dominant 
underlying mechanism or mechanisms. 
Factors that contribute to anaemia in patients with nonhaematological 
malignancy8,9 
Common factors 
• Blood loss 
• Infections 
• Chronic ‘inflammatory – like’ response 
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Less common factors 
• Bone marrow infiltration 
• Inadequate nutrition 
• Impaired  renal function 
• Haemolysis 
• Myelosuppressive effects of treatment10   
BLOOD LOSS 
Anaemia due to blood loss develops extremely commonly in carcinoma of the 
stomach and colon and is particularly important as it may be the presenting 
manifestation which antedates symptoms referable to the alimentary tract. 
 INFECTION 
Infection may be an important contributing factor to anaemia in 
malignancy, such as carcinoma of bronchus or fungating lesion at any site. The 
mechanism by which the anaemia is produced is as previously considered under 
anaemia of chronic disorders, a mechanism that can also operate in the absence 
of infection in subjects with advanced malignant disease. 
METASTASIS TO BONE MARROW 
Metastasis to bone marrow occurs in about 20% of all fatal cases of 
nonhaematological malignancy. After the lungs and the liver, the bone marrow is 
the next most common site of ‘blood-borne’ metastases. Breast and prostate 
cancer are the primary tumours that most frequently metastasize to bone, but 
carcinoma of the lung, kidney, thyroid, and stomach and malignant melanoma 
also commonly metastasize there. Metastatic growth most frequently occurs in 
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the sites normally occupied by red bone marrow, namely the vertebrae, ribs, 
sternum, pelvis, skull, and upper ends of the femur and humerus. 
Anaemia is common in patients with secondary carcinoma of the bone 
marrow, but it can be absent even when widespread bone involvement is 
demonstrated by X-ray. Many factors in patients with advanced metastatic 
disease can contribute to the genesis of anaemia - malnutrition, infection, blood 
loss, micro-angiopathy and effects of the type that produce the anaemia of 
chronic disorders - let alone replacement of haematopoietic tissue by tumour 
cells. The latter most frequently is not the major cause of the anaemia, in 
contrast to the situation in, for example, acute leukaemia.    
In marrow metastasis, there may or may not be anaemia. When anaemia 
is present, it is usually normochromic and normocytic. A finding of diagnostic 
significance indicating the presence of marrow metastasis is a leuco-
erythroblastic blood picture, in which nucleated red cells and granulocyte 
precursors are present. Other features are anisocytosis, poikilocytosis and 
occasional macrocytes and polychromatic cells. Sometimes a moderate 
leucocytosis is present, and sometimes a moderate degree of leucopenia, 
although the white cell count is rarely less than 2 X 109/L. 
Interference with nutritional intake caused by anorexia, vomiting, 
dysphagia etc,. can contribute to the production of anaemia by impairing the 
intake or absorption of nutrients necessary for erythropoiesis, especially iron and 
folate, but it is rarely the soul cause of anaemia. Megaloblastic macrocytic 
aneamia associated with carcinoma of the stomach is usually due to the 
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development of carcinoma in a patient with gastric atrophy associated with 
pernicious anaemia . 
HAEMOLYTIC ANAEMIA: 
 Some shortening of red cell lifespan is common in disseminated 
malignancy, and is of importance since it may result in an unsatisfactory 
response to blood transfusion. A relatively uncommon, but definitely associated, 
form of severe haemolysis is micro- angiopathic hemolytic anaemia , which is 
seen particularly in metastatic mucin-secreting adenocarcinomas11. 
In order to understand the pathophysiology of the iron deficiency anaemia 
and anaemia of chronic disease, the iron metabolism is considered here in detail. 
IRON METABOLISM 
Most of the iron is present in the oxygen carrying protein of the red blood 
cells-haemoglobin. Iron turnover is also dominated by the synthesis and 
breakdown of haemoglobin. Haem is synthesis in nucleated red cells in the bone 
marrow by a pathway ending with the incorporation of iron into protoporphyrin IX 
by ferrochelatase. Haem breakdown takes place in phagocytic cells, largely 
those in the spleen, liver and bone marrow. Iron is released from haem by haem 
oxygenase and is largely reused for haem synthesis. Every day about 30 mg of 
iron are used to make new haemoglobin and most of this is obtained from the 
breakdown of old red cells. 
Relatively little iron is lost from the body (about 1mg/day in men) and 
these losses are not influenced by body iron content or the requirement of the 
body iron. The body iron content is maintained by variation in amount of iron 
absorbed. 
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In most men and postmenopausal women there is some storage iron. This 
is iron in ferritin or its insoluble derivative haemosiderin, which is available for 
haem synthesis if necessary. 
DIETARY IRON ABSORPTION 
Iron absorbed depends on12  
• the amount of iron in the diet 
• its bioavailability  
• the body’s need for iron 
• erythropoietin concentration 
• age  and 
• inflammatory states with hepcidin release.  
Nonhaem iron is released from food as Fe3+ and reduced to Fe2+ by a             
membrane – bound, ferrireductase, Dcytb. 
 Iron is transported across the brush-border membrane by the metal 
transporter,       DMT-1.Some iron is incorporated into ferritin and lost when the 
cells are exfoliated. 
 Iron destined for retention by the body is transported across the serosal 
membrane by ferroportin-1. Before uptake by transferrin, Fe2+ is oxidised to Fe3+ 
by hephaestin or by plasma ceruloplasmin. 
   Haemoglobin and myoglobin are digested in the stomach and small 
intestine. Haem is initially bound by haem receptors at the brush border 
membrane and the iron is released intracellularly by haem oxygenase before 
entering the labile iron pool and following a common pathway with iron of 
nonhaem origin13. 
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REGULATION OF IRON ABSORPTION 
Iron absorption may be regulated both at the stage of mucosal uptake and 
at the stage of transfer to the blood. As epithelial cells develop in the crypts of 
Lieberkuhn  their iron status reflects that of the plasma (transferring saturation) 
and this programmes the cells to absorb iron appropriately as they differentiate 
along the villus. 
Transfer to the plasma depends on the requirements of the erythron for 
iron and the level of iron stores. This regulation is mediated directly by hepcidin, 
a peptide synthesized in the liver in response to iron and inflammation. Hepcidin 
blocks intestinal iron absorption and iron release from liver and spleen. The main 
mechanism by which hepcidin exerts its effects appears to be control of 
ferroportin. Indeed, ferroportin is the only known cellular iron exporter, which 
cannot mediate iron release from the cell once hepcidin exerts its actions.  
CELLULAR IRON UPTAKE AND RELEASE 
 Transferrin binds to the transferring receptor (TfR) lining the cell. The two 
proteins bind strongly to form a high affinity complex which initiates endocytosis 
of the local membrane. The resulting endosome contains the transferrin- 
transferrin receptor complex. The pH of the endosome is then reduced by a 
proton pump to induce a conformational change in holotransferrin, which 
releases its iron. Iron is transported into the cell via DMT-1.This iron is then either 
stored as ferritin or used within the cell (for Hb synthesis in erythroid 
precursors).The apotransferrin and the transferrin receptor return to the cell 
surface where they dissociate at neutral pH so that the cycle can start again. 
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The reticuloendothelial macrophages play a major role in recycling iron 
resulting from the degradation of haemoglobin from senescent erythrocytes. 
They engulf red blood cells and release the iron within using haem oxygenase. 
The iron is rapidly released to plasma transferrin or stored as ferritin. Little is 
known about the mechanism of release, but ferroportin 1 may be an essential 
component. 
Ferritin is found in all cells and in the highest concentration in liver, spleen 
and bone marrow13. 
With the recognition that the small quantity of ferritin in human serum                      
(15- 300 μg/L in healthy men) reflects body iron stores, measurement of serum 
ferritin has been widely adopted as a test for iron deficiency and iron overload. 
ERYTHROPOIETIN 
EPO is an important erythropoiesis activating hormone. The recombinant 
synthesized molecule is called epoetin (rHuEPO). EPO is a glycoprotein with a 
molecular weight of 34 kDa. The core of the molecule is a peptide of 165 amino 
acids, which is responsible for receptor binding of the hormone. The 
carbohydrate part makes up for about 40% of the molecule and is of pivotal 
importance for in vivo function of the hormone. This carbohydrate component is 
highly variable and exists in various isoforms with different biological activity.  
During foetal growth, EPO is predominantly synthesized in the liver. In 
adult life, however, EPO is predominantly synthesized in peritubular endothelium 
cells of the kidney with only 20% contribution to overall EPO production from 
hepatocytes. Synthesis of EPO is regulated by hypoxic stimulation, which 
triggers transcriptional upregulation. Reduction in circulating haemoglobin 
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concentration triggers an exponential increase in EPO concentration. 
Concentration of circulating EPO is not mediated via release from intracellular 
storage but rather depends on direct regulation of gene expression.  
EPO action and EPO receptor 
Erythrocyte precursor cells such as proerythroblasts and colony forming 
units-erythroid (CFU-E) are the primary targets of EPO. Only a fraction of these 
precursor cells mature while a great proportion undergo apoptosis in the absence 
of EPO. The differentiation  of pluripotent stem cells via intermediate stages into 
CFU-E occurs even in the absence of EPO.                   
EPO acts through specific EPO receptors. The number of receptors 
declines continuously during cell differentiation, and no receptor expression is 
found in reticulocytes and erythrocytes. It is interesting to note that the affinity of 
EPO to its receptor depends on its carbohydrate portion. A higher content in 
carbohydrate leads to a decrease in receptor affinity. Such knowledge helps in 
understanding the prolonged plasma half-life in certain genetically engineered 
EPO analogues such as darbepoetin-alpha. 
There are a number of pleiotropic effects of EPO beyond regulation of 
haematopoiesis. These are partly due to the fact that EPO receptors have been 
identified in a number of different tissues such as skeletal muscle, smooth 
muscle and the myocardium. EPO receptors are further expressed within the 
brain and spinal cord, in the lungs, kidneys, bowel, pancreas, uterus, retina and 
in the gonadal glands. EPO protects neurons from hypoxia-induced damage12. 
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Erythropoietin resistance 
Up to 90% of the anaemia patients treated with EPO respond to this 
therapy with a significant increase in haemoglobin. The remaining 10% of 
patients, however do not show a sufficient increase in haemoglobin although high 
doses of epoetin had been administered or an initially appropriate response to 
EPO was lost in the course of EPO therapy. 
The underlying mechanisms include 
• Iron deficiency 
• Inflammatory activation 
• Blood loss  
• Hyperparathyroidism 
• Aluminium induced toxic effects 
• Deficiency of vitamin B12 or folic acid 
• Haemolysis 
• Impaired erythropoiesis 
• Haemoglobinopathy 
• ACE inhibitor therapy and rarely, 
• Antibodies against EPO. 
ANAEMIA OF CHRONIC DISEASE 
PATHOPHYSIOLOGY 
The anaemia of chronic disease is of immunological origin. In the clinical 
setting, it is mostly found in patients with chronic inflammatory processes, chronic 
infectious diseases, and in patients with malignant tumours. Perturbations in iron 
homeostasis can be found that are associated with an increased uptake and 
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retention of iron in the cells of the reticuloendothelial system. This leads to the 
deposition of iron in the cells of the reticuloendothelial system, which, in turn 
yields a lack of iron for erythropoiesis. The increase in iron storage appears to be 
mediated by pro-inflammatory cytokines. Tumour necrosis factor-alpha, for 
example, inhibits synthesis of the iron storage protein ferritin in macrophages and 
hepatocytes. Additionally, the expression of the membrane protein DMT-1 is 
upregulated by interferon-gamma, bacterial lipopolysaccharide and  tumour 
necrosis factor-alpha. This protein mediates iron transport into the intestinal 
mucosal cell as well as into activated macrophages. Moreover, export of iron 
from these cells is inhibited through downregulation of the expression of 
ferroportin. Hepcidin appears to play a central role in this setting, because it is 
more abundantly expressed under the influence of lipopolysaccharide and 
interleukin-6 secretion. This, in turn, yields an additional inhibition of iron 
absorption from the gut. Furthermore, the action of aforementioned cytokines, 
especially that of interferon-gamma, leads to a direct suppression of 
erythropoiesis. It has been proposed that the responsible mechanisms are an 
induction of apoptosis and an inhibition of erythropoietin expression. 
In addition to the effects of iron sequestration, inflammatory cytokines 
promote the production of white blood cells16. Bone marrow produces both red 
blood cells and white blood cells from the same precursor stem cells. Therefore, 
the upregulation of white blood cells causes fewer stem cells to differentiate into 
red blood cells. This effect may be an important additional cause for the 
decreased erythropoiesis seen in anaemia of inflammation, even when 
erythropoietin levels are normal, and even aside from the effects of hepcidin.  
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In the short term, the overall effect of these changes is likely positive: it 
allows the body to keep more iron away from bacterial pathogens in the body, 
while producing more immune cells to fight off infection. Bacteria, like most life 
forms, depend on iron to live and multiply. However if inflammation continues, the 
effect of locking up iron stores is to reduce the ability of the bone marrow to 
produce red blood cells.     
CLINICAL PROFILE  
The anaemia of chronic disease presents itself as a normochromic 
normocytic anaemia14. It normally does not lead to a decrease in haemoglobin 
below 8 g/dL. The diagnosis is usually established by a low serum iron 
concentration, a low transferrin concentration, a low transferrin saturation, and 
normal or increased ferritin values in the presence of a chronic illness15,16.  The 
number of reticulocytes is usually low, which points to a small rate in de novo 
production. Serum values of iron and transferrin saturation are normally reduced, 
because the iron is trapped inside the reticuloendothelial system17. Assessing C-
reactive protein values is usually helpful to differentiate acute inflammatory 
processes16.         
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Table 2 Underlying Causes of Anaemia of Chronic Disease18 
 
Associated Diseases 
 
Estimated Prevalence 
 
Infections (acute and chronic) 
   Viral infections including HIV 
   Bacterial 
   Parasitic  
   Fungal 
 
18 - 95% 
 
 
Cancer* 
   Haematological 
   Solid tumour 
 
30 – 77% 
Autoimmune 
   Rheumatoid Arthritis 
   Systemic lupus erythematosis and  
   connective tissue diseases 
   Vasculitis 
   Sarcoidosis 
   Inflammatory bowel disease 
 
8 – 71% 
 
 
 
Chronic rejection after solid organ         
transplantation 
8 – 70% 
Chronic kidney disease and 
inflammation 
 
 
23 – 50% 
      
*The prevalence of anaemia in patients with cancer is affected by therapeutic 
procedures and age. A high prevalence was reported in one study in which 77% 
of elderly men and 68% of elderly women with cancer were anaemic19. In another 
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study, anaemia was observed in 41% of patients with solid tumours before 
radiotherapy and in 54% thereafter20. 
ANAEMIA MANAGEMENT WITH ERYTHROPOIESIS STIMULATING 
AGENTS: RISKS AND BENEFITS   
More than 80% of cancer patients undergoing chemotherapy develop 
anaemia (Hb <12g/dL), and the need for blood transfusion is frequent11. 
Erythropoiesis Stimulating Agents (ESAs) were developed with the aim of 
reducing transfusion dependence, and meta-analyses of clinical trials confirm 
that they have been highly successful in achieving this7,21,22. 
The systematic review by Bohlius et al 23. incorporated data from a total of 
9353 cancer patients, with tumours including those of the breast, lung, and 
gastrointestinal tract, treated in 57 trials. Treatment with epoetin or darbepoetin 
significantly reduced the need for transfusion (relative risk, 0.64; 95% confidence 
interval, 0.60 – 0.68), and the chance of achieving a haematological response 
was consistent across tumour types 24,25.These findings were supported by the 
2006 analysis of the Agency for Healthcare Research and Quality26. Both meta-
analyses noted a slightly higher risk for venous thromboembolic events in 
patients administered epoetin or darbepoetin, and were suggestive that this risk 
was associated with higher Hb levels. 
ESAs have the advantage of avoiding the fluctuations in Hb level 
associated with RBC transfusions, as well as reducing the risks for disease 
transmission and the cardiac and hepatic consequences of iron overload (an 
issue in patients with haematological malignancies). Furthermore, under 
controlled conditions, RBCs can be stored for up to 42 days prior to transfusion, 
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and this is a potential source of problems. Indeed, in retrospective studies, a 
correlation was found between the duration of RBC storage and the mortality 
rates after transfusion27. Variations can occur in stored RBCs over time, which 
may include changes in RBC-dependent vasoregulatory function and                          
S-nitrosohaemoglobin (SNO-Hb), and RBC deformability. Changes can occur 
even soon after blood collection, where SNO levels (and their physiological 
correlate RBC-dependent vasodilation) become depressed. Thus, changes may 
occur in stored RBCs that impact the function of the RBCs and can affect clinical 
outcomes.  
In the 13 years since recombinant erythropoietin was first approved for the 
treatment of cisplatin – related anaemia, around four million patients have been 
treated with ESAs; and their quality of life (when symptoms have been anaemia 
related) has been greatly improved as a consequence28,29      
ERYTHROPOIETIN RECEPTORS ON TUMOUR CELLS 
Given the apparent presence of erythropoietin receptors (EPORs) in 
cancer tissues30, questions have been raised about the possible influence of 
erythropoiesis – stimulating  agents (ESAs) on tumour growth and proliferation. 
In 2003, Henke et al31 published the results of a study of patients with head and 
neck cancer undergoing radiation therapy who were randomized to a control 
group or additional treatment with epoetin beta (300 U/kg). The purpose of the 
study was to investigate the potential radiosensitizing effects of raising the level 
of haemoglobin towards a target value of 14 g/dL in women and 15 g/dL in men. 
Epoetin beta treatment effectively raised the haemoglobin level, but was 
associated with significantly shorter progression-free and overall survival times. 
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A subsequent report presented data on the erythropoietin receptor status 
in tissue samples from 154 patients who were among the 351 patients enrolled in 
the randomized controlled trial. This retrospective analysis assessed the effect of 
epoetin beta on progression – free survival in relationship to EPOR expression. 
Staining studies used C20 antibody. Around two thirds of samples stained 
positive and, among this EPOR-positive group of patients, the local disease-free-
survival rate was significantly lower in patients treated with epoetin than among 
controls. Among the smaller number of patients whose tumour tissue did not 
stain for the EPOR, there was no significant difference in outcome between the 
placebo and treated groups. 
           These findings raised the question of whether the presence of EPOR 
might stimulate tumour cell growth when bound by EPO or an EPO-like ligand32. 
However, the basis for such a study is the presumption that the EPOR antibody 
detects what it is meant to detect, and not other proteins; and it is by no means 
clear that this is the case. Data from several groups suggest that the antibodies 
currently available are not valid tools for determining the EPOR status of tissue 
sections obtained form cancer patients. 
EPOR gene is not an oncogene, and there is no selective advantage for 
tumours to overexpress it. EPO mRNA is detectable in tumour cell lines, but is 
not elevated compared with nontumour tissues. Tumour cell lines show no or 
only weak binding to EPO. Surface expression of EPORs on tumours has not 
been unambiguously demonstrated. In fact, most of the staining is in the 
cytoplasm, a site in which the receptor cannot, of course, bind its ligand33. 
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In more than 25 malignant and benign human cell lines, EPO did not 
increase the proliferation rate of EPOR-positive tumour cell lines, nor did it affect 
c-fos mRNA expression in these cell lines34. Collectively, the majority of in vitro 
studies have shown that ESAs are likely to have a neutral effect on human 
cancers. 
           Examination of the amino acid sequence of the purported EPOR 
demonstrated by Western blotting revealed that it was not that protein at all but 
one of the several isoforms of heat shock protein (HSP) 70. C20 recognized       
HSP 70 almost exclusively. This fact is of interest to oncologists because HSP 70 
is a highly conserved family of chaperone proteins that are induced in normal 
cells by stress and that have important functions in promoting cell survival and 
resistance to apoptosis35. They are found in tumors, particularly those of an 
aggressive phenotype. Expression correlates with shorter survival and resistance 
to treatment in many tumours.  
          For this reason, results from clinical studies purporting to relate the 
administration of ESAs to shorter survival must be considered inconclusive and 
complicated by methodological and sampling issues. Ongoing studies will help 
clarify whether the existence of the EPOR has any relevance at all in the cancer 
setting.    
      A working party of the European Organisation for Research and 
Treatment of Cancer met in September 2007 to update the Organisation’s 2006 
guidelines on use of Erythropoietic Stimulating Agents. In brief, the EORTC 
Working Party’s conclusions and recommendations are now as follows36: 
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ESAs should be initiated at an Hb level of 9-11 g/dL in cancer patients 
receiving chemotherapy or radiochemotherapy, based on anaemia – related 
symptoms. 
ESAs may be considered in selected asymptomatic chemotherapy 
patients with an Hb level of 11–11.9 g/dL if this would prevent a further decline in 
Hb; such a decision should take into account an individual’s Hb level prior to 
chemotherapy and the type, intensity, and duration of chemotherapy or other 
planned treatment. 
ESAs are not recommended for prophylaxis of anaemia in patients with 
normal Hb values prior to undergoing chemotherapy and/or radiotherapy. 
ESAs may be given in selected patients with cancer-related anaemia not 
undergoing chemotherapy or radiotherapy with an Hb level of 9 – 11 g/dL if 
justified by anaemia – related symptoms and careful assessment of need. Note: 
In certain countries this is not an approved indication. 
The target of treatment with ESAs is to achieve an Hb level of about                       
12 g/dL. 
In patients not responding in 4 – 8 weeks, there is no recommendation 
that dose escalation should be the general approach. 
In responding patients, treatment should be continued until an Hb level of 
around 12 g/dL is reached and patients show improved symptoms37. Further 
treatment of patients reaching the target Hb level should be individualized using 
an increased dosing interval and/or titrating downwards to the lowest effective 
maintenance dose. 
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There is no evidence that oral iron supplements increase response to 
erythropoietic proteins. There is evidence of a better response to erythropoietic 
proteins with i.v. iron. However, i.v. iron use should be reserved for patients with 
absolute or functional iron deficiency. 
Combining the data from all available studies indicates that using ESAs to 
treat anaemia in cancer patients leads to a 1.6 fold higher risk for 
thromboembolic events. 
Epoetin alfa and epoetin beta can be given on a fixed – dose weekly 
basis. 
Darbepoetin can be used on an every -3-week, fixed-dose basis, or once 
weekly at 2.25 μg/kg. Certain countries also use a 2-week regimen.    
 UNDERSTANDING THE IMPACT OF ANAEMIA 
In 1951 Hollaender et al. published their study on the radiosensitivity of 
aerobically and anaerobically cultured Escherichia coli38. Their study helped form 
the foundation of current thinking on tumour hypoxia and its effects on 
radiotherapy. Under hypoxic conditions, tumours appear to be less susceptible to 
radiation, and clinical  outcomes are poorer39. A recent study investigated the 
relationship between tumour hypoxia and tumour control and survival in patients 
with cervical cancer undergoing radiotherapy. The results of tumour oxygenation 
measurements taken prior to radiotherapy by an Eppendorf oxygen electrode 
and measured by the Eppendorf pO2 histograph indicate that tumour hypoxia is 
associated with an increased risk of relapse and death, particularly in patients 
with bulky hypoxic tumours. Tumour oxygenation was significantly associated 
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with disease-free survival (p=0.02), as was tumour size (p=0.0003), stage 
(p=0.006), and pretreatment haemoglobin level (p=0.001) 40. 
The association between anaemia and tumour hypoxia is not fully 
understood, but it is well established that low haemoglobin levels independently 
predict poorer survival and relapse41,42. However it is not clear whether low 
haemoglobin levels are associated with poor survival because they indicate 
advanced disease or because they indicate poor tumour oxygenation. Current 
thinking, however, recognizes anaemia as a likely contributor to tumour hypoxia43 
with a focus on anaemia and locoregional failure. 
 The impact of anaemia on survival and relapse after radiotherapy has 
been investigated for a number of tumour types. A recent study looked at the 
association between anaemia and overall survival and local tumour control in 
patients with locally advanced head and cancer undergoing radiation therapy44. 
Patients were stratified by haemoglobin levels and were given either radiotherapy 
with a hypoxic cell sensitizer,etanidazole, or radiation therapy alone. The survival 
rate at five years for patients with anaemia – defined as haemoglobin 
concentration  <14.5 g/dL for men and <13 g/dL for women – was 22%. For 
nonanaemic patients the rate at five years was 36% a significant increase 
compared with anaemic patients (p=0.0016). Treatment with etanidazole did not 
significantly improve survival among any group of patients. Locoregional failure 
at five years differed significantly between patients with  or without anaemia. 
Patients with normal haemoglobin levels experienced locoregional failure at a 
rate of 52% compared with 68% for anaemic patients (p=0.00028). Again, the 
addition of etanidazole did not significantly affect locoregional control among any 
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group of patients. Anaemia was significantly related to decreased survival and 
increased relapse rates. 
A strong correlation between haemoglobin levels, local control, and 
survival was also observed in a study of 109 patients with T1 – T2 squamous cell 
carcinoma of the glottic larynx treated with definitive radiotherapy45. Patients who 
presented with haemoglobin values >13 g/dL had significantly higher two–year 
rates of locoregional tumour control ( 95% versus 66%, p=0.0018) and survival 
(88% versus 46%, p=0.001) as compared with patients with haemoglobin values 
<13 g/dL. 
Improving the efficacy of radiation therapy and, therefore, locoregional 
response and survival, may be achieved by addressing anaemia and tumour 
hypoxia. Recent studies have investigated strategies that reduce anaemia and 
tumour hypoxia such as hypoxic cell sensitizers, fluosol, carbogen breathing, 
hyperbaric oxygen, red blood  cell transfusions, and recombinant human 
erythropoietin (epoetin alfa). In a study of patients with head and neck cancer 
given radiation and mitomycin C, a hypoxic cell sensitizer, or radiation alone, the 
data showed that the addition of mitomycin C significantly improved local 
recurrence-free survival and cause-specific survival. In a preliminary study, 
advanced head and neck cancer patients treated with daily chemoradiotherapy 
received carbogen breathing, blood transfusions, or erythrppoietin to increase 
their haemoglobin levels to nonanaemic levels (>13 g/dL) in order to overcome 
tumour hypoxia . A 100% complete response rate was observed. At 18 months, 
6% had local recurrence and 14% had distant metastasis. Carbogen breathing 
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and anaemia correction resulted in improvements in local control, cause-specific 
survival, and overall survival46. 
Aggressive management of anaemia, when incorporated into the overall 
management strategy for advanced head and neck cancer, has the potential to 
provide significant improvements in clinical outcomes. In addition to the head and 
neck data just discussed, opportunities exist in other sites. 
In patients with cervical cancer undergoing radiotherapy with or without 
chemotherapy, those who maintained an average nadir weekly haemoglobin 
level (ANWH) above 12 g/dL experienced a decrease in pelvic and distal 
recurrence (p<0.0001 and p=<0.0005, respectively) compared with those whose 
ANWH fell below 12 g/dl. In this study, patients whose haemoglobin fell below             
10 g/dL, 11 g/dL, or 12 g/dL, depending on the study site, received blood 
transfusions in order to maintain  ANWH above these levels47.  Finally, in patients 
with advanced cervical cancer, those patients who maintained haemoglobin 
levels above 10 g/dL during radiotherapy had improved locoregional tumour 
control compared with those patients whose on-therapy values fell below             
10 g/dL (p<0.01)48. 
Professional awareness of the human and economic costs of anaemia in 
patients with cancer has progressed substantially in the last decade49. Most 
recently, research completed by The Fatigue Coalition has revealed the profound 
burden that fatigue imposes on patients with cancer and their caregivers50. In 
turn, recent studies have shown that modest improvements in haemoglobin 
concentrations can result in significant improvements in patient QOL. A recent 
study of epoetin alfa use in patients receiving chemotherapy demonstrated that 
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increases in haemoglobin of less than 2 g/dL resulted in significantly improved  
QOL according to a questionnaire (Functional Assessment of Cancer Therapy- 
Anaemia; FACT-An) and linear analog scale assessment                     
(LASA)51.QOL improvements were observed independent of response to 
chemotherapy. Another study of erythropoietin use in patients undergoing 
chemotherapy demonstrated significant improvements in LASA scores, indicating 
improvement in QOL. The mean increase in haemoglobin in this study was only 
1.8 g/dL52. 
Even modest anaemia  has a detrimental effect on clinical outcomes53. 
Dubray54 reported a study of head and neck cancer patients receiving 
radiotherapy and demonstrated that high pretreatment haemoglobin significantly 
related to higher survival rates. In this study, those with anaemia had functional – 
defined as Hb <12 g/dL, not physiologic – defined as Hb 8 g/dL or less, anaemia. 
All but 3 of 63 patients with anaemia – defined as haemoglobin <13.5 g/dL for 
men and haemoglobin< 12.0 g/dL for women – had haemoglobin > 10 g/dL.  
THE EUROPEAN CANCER ANAEMIA SURVEY 
That the impact of anaemia is not always fully appreciated is highlighted 
by the results of the European Cancer Anaemia Survey (ECAS) 55, 56, 57. A large, 
prospective, epidemiologic, observational study conducted in 24 European 
countries, ECAS enrolled and collected data on 15,367 patients with various solid 
and haematological malignancies treated at 748 academic, community, and 
private centres specializing in cancer care. The objective of the survey was to 
determine the prevalence and incidence of cancer-related anaemia, anaemia 
management practices, and risk factors for anaemia development in the 
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European cancer community. Importantly, ECAS not only demonstrated the high 
prevalence and incidence of cancer – related anaemia but also revealed that 
anaemia treatment was often suboptimal, either not being offered at all or being 
initiated only after the patient’s haemoglobin level had dropped to a mean of                   
9.7 g/dL. Moreover, for one third of chemotherapy patients who received epoetin 
and for more than half of chemotherapy patients who received transfusion, 
anaemia treatment was not offered until their Hb levels had declined to < 9 g/dL. 
Logistical regression analyses in the overall European Cancer Anaemia 
Survey population identified five factors as significant and suitable predictors of 
anaemia: lower initial Hb, having lung or gynaecologic cancer versus 
gastrointestinal / colorectal cancer, any other cancer versus gastrointestinal / 
colorectal cancer, platinum chemotherapy and being female56.                     
THE POLISH CANCER ANAEMIA SURVEY 
  The purpose of POLCAS58, the retrospective multicentre study in cancer 
patients in Poland was to analyse the frequency of anaemia and methods of its 
treatment. An attempt was also made to evaluate the haemoglobin levels in 
relation to patient’s performance status prior to and after anticancer treatment. A 
total of 999 patients were enrolled, who were followed up to six chemotherapy 
cycles or six evaluation points within a 6-month period. 
The incidence of anaemia at the time of enrolment into the study equaled 
31%, and was observed mainly among gynaecologic and colorectal cancer 
patients. After anticancer treatment, anaemia was reported in 54%of patients, 
mainly gynaecological and lung cancer patients. As many as 71%of patients 
were anaemic at some point of time during the survey, which was most often 
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documented among gynaecological, lung and testicular cancer patients. At the 
fifth visit more than 50%of patients were anaemic. The difference between the 
mean Hb level at first and sixth visit was 1.04 g/dL. However, anaemia was 
treated in only 32% of patients (red blood cell transfusions 61%, iron 
supplementation 33% while erythropoietic stimulating proteins in just 6%).Worse 
performance status was observed in anaemic patients with lung cancer and head 
and neck cancer. 
THE AUSTRALIAN CANCER ANAEMIA SURVEY 
The Australian Cancer Anaemia Survey (ACAS)59 was initiated to create a 
‘snapshot’ database documenting prevalence, incidence, frequency and 
management of anaemia in the adult cancer patients attending oncology 
departments in Australia, and to identify patient and treatment characteristics 
associated with anaemia. 
 ACAS was a 6-month observational, prospective, multicentre study of 694 
patients recruited from outpatient oncology clinics in 24 hospitals in five 
Australian states between 9 April 2001 and 31 July 2001. 
 Prevalence of anaemia at enrolment was 35%. Frequency of anaemia 
(either present at enrolment or developing during the study) was 57% and varied 
with tumour type , from 49% (lymphoma / myeloma) to 85% urogenital cancer. 
 Patients who received radiotherapy either in combination or concomitant 
with chemotherapy were more likely to have anaemia (73%) than those receiving 
chemotherapy alone (58%). Of all chemotherapy patients not anaemic at 
enrolment, 23% developed anaemia by the second month follow up. Independent  
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predictors for anaemia in chemotherapy patients were low baseline Hb level and 
use of platinum chemotherapeutic agents. 
Anaemia was treated in 41% of patients with anaemia at enrolment – by 
transfusion (36%), iron (5%) and erythropoietic agents (2%). Frequency of 
anaemia treatment varied between tumour types, from 19% (breast cancer) to 
60% (leukaemia). The mean trigger Hb for initiating transfusion was 9.5 g/dL.     
DEFINING ANAEMIA IN CANCER 
According to September 2007 Update on the European Organization for 
Research and Treatment of Cancer guidelines, the target of treatment with 
Erythropoiesis – Stimulating Agents is to achieve an Hb concentration of about 
12 g/dL in cancer related anaemia36. 
American Society of Hematology / American  Society of Clinical Oncology 
2008 updated guidelines on the use of ESAs also states that Hb can be raised to 
(or near) a concentration of  12 g/dL, at which time the dosage of epoetin or 
darbepoetin should be titrated to maintain that level37.  
That is why, numerous large scale studies on cancer related anaemia like 
ECAS55, ACAS59, POLCAS58 and others have defined anaemia as Hb < 12g/dL.  
DIFFERENTIAL DIAGNOSIS 
In cancer patients with anaemia, the major differential diagnosis is iron 
deficiency anaemia. This is not a trivial distinction. The diagnosis of iron 
deficiency anaemia mandates identification of a source of blood loss. Incorrectly 
labeling a patient with anaemia of chronic disease as iron deficient exposes the 
patient to intrusive and expensive (although fairly safe) diagnostic procedures 
and to ineffective therapy. Mislabeling an iron deficient patient as having 
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anaemia of chronic disease may result in failure to diagnose an underlying 
gastrointestinal malignancy at a curable stage and in failure to offer inexpensive 
and effective therapy. 
Table – 3. Serum Values to Differentiate Anaemia of Chronic Disease from 
Iron Deficiency Anaemia 
 Anaemia of chronic 
disease 
Iron deficiency 
anaemia 
Both 
Iron 
  
Transferrin              
Transferrin 
saturation 
Ferritin 
Soluble Transferrin 
receptor 
 
 
  
Ratio of soluble 
Transferrin 
receptor to log 
ferritin 
 
     Low(<1) 
 
     High(>2) 
 
     High(>2) 
Cytokine Levels  
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Evaluation of anaemia begins with haemoglobin estimation, peripheral 
smear examination and very rarely serum ferritin, iron and TIBC are done. 
However, these tests are not cost effective and do not depict the exact bone 
marrow iron stores in conditions associated with infection/inflammation. In 
differentiating between iron deficiency anaemia and anaemia of chronic disorders 
these investigations are of limited value60. 
Serum Ferritin level of 12 μg/L is mostly used for historical point of view. 
This value has a high specificity, but an unacceptably low sensitivity. E Joosten 
et al.16 in a study found a lower reference limit of 50 μg/L for serum ferritin, the 
best discriminant between Iron deficiency anaemia (IDA) and non-IDA in an 
elderly population. This is in agreement with the guidelines published in a recent 
study by Ioannou et al. where iron deficiency was defined as a serum ferritin level 
45 μg/L. 
In a recent single institution experience, all patients with serum ferritin 
levels below 30 μg/L were iron deficient by marrow examination as were the 
majority of hospitalized patients with serum ferritin levels 30 to 100 μg/L and 
approximately one-third of hospitalized patients with serum ferritin levels between 
100 and 200 μg/L. Combining the serum ferritin level with other parameters such 
as erythrocyte sedimentation rate and C-reactive protein, did not improve its 
predictive value61. 
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                                       MATERIAL AND METHODS 
This study was carried out in the department of Clinical Pathology on the 
patients admitted to Coimbatore Medical College Hospital, Coimbatore, during 
the period of February to August 2009. 
INCLUSION CRITERIA 
1. Patients with nonhaematological malignancies aged 19–69 years with                        
Hb < 12 g/dL 
2. Newly diagnosed                                 
3. No prior chemo or radiotherapy and 
4. No prior steroid administration. 
EXCLUSION CRITERIA 
1. Patients in relapse 
2. Patients on chemo or radiotherapy 
3. Prior surgery for the same and 
4. Systemic illnesses like Cardiac, Renal or Hepatic disease (severe enough 
to affect haematopoisis). 
SAMPLE SIZE 
A total number of 40 inpatients with various nonhaematological 
malignancies were screened for anaemia. Based on Hb cut-off of 12 g/dL, 33 of 
them were recruited for the study. Since we receive about 1200 samples of 
nonhaematological malignancies in our department in a year, it represents about 
2.75% of the incidence in our department. 
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METHODOLOGY 
Newly diagnosed patients admitted to various surgical and gynaecological 
wards were randomly selected for the study as per  the inclusion and exclusion 
criteria.     
  Detailed history was obtained from the patients regarding the present 
illness (malignancy), blood loss, haematemesis, malaena, haemoptysis, any 
bleeding or thrombotic tendency, appetite, vomiting, bowel habits, dyspnoea, 
bone pain, etc,. History of drug intake like aspirin or any previous treatment for 
anaemia were obtained. Tissue diagnosis either by biopsy or fine needle 
aspiration cytology was obtained for all the cases. Other investigations like CT , 
MRI  and ultrasound scans and X ray films were scrutinized. 
  Patients were examined for nutritional status, tenderness over the bones, 
pathological fractures, pallor, cyanosis, paedal oedema, dyspnoea, clubbing, 
jaundice, lymphadenopathy, liver or spleen enlargement.  
All the patients included in the study underwent the following investigations: 
• Complete haemogram 
• Peripheral smear study 
• Liver function tests (SGOT, SGPT &Alkaline Phosphatase) 
• Renal function tests (Blood Urea, Serum Creatinine) 
• Blood sugar 
• Urine analysis  and  
• Serum proteins.                
• Serum iron, total iron binding capacity and serum ferritin.  
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Algorithm for investigation 
       Hb                                     
 
 Hb=/> 12 g/dL (excluded from the study) 
       Hb < 12 g/dL      
 
 
     (Recruited for the study) 
     Further investigations                                                                                                          
Complete Haemogram was done using Sysmex KX-21, fully automated 
haematology analyzer (manufacturers: Sysmex Corporation, Japan).  
DETECTION PRINCIPLE 
This instrument performs blood cell count by DC detection method. Blood 
sample is aspirated, measured to a predetermined volume, diluted at the 
specified ratio, then fed into each transducer. The transducer chamber has a 
minute hole called the aperture. On both sides of the aperture, there are the 
electrodes between which flows direct current. Blood cells suspended in the 
diluted sample pass through the aperture, causing direct current resistance to 
change between electrodes. As direct current resistance changes, the blood cell 
size is detected as electric pulses.Blood cell count is calculated by counting the 
pulses, and a histogram of blood cell sizes is plotted by determining the pulse 
sizes. Also, analyzing a histogram makes it possible to obtain various analysis 
data. 
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Figure 3. Cell Counting Principle 
 
Figure 4 .RBC & Platelet Counting 
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NON-CYANIDE HAEMOGLOBIN ANALYSIS METHOD 
To analyze haemoglobin by automated methods, the 
Cyanmethaemoglobin method or Oxyhaemoglobin method have so far been the 
mainstream.  
Cyanmethaemoglobin method was recommended as the international 
standard method in 1966 by ICSH (International Committee for Standardization 
in Haematology). This method, however, so low in haemoglobin conversion rate 
that it cannot be said an appropriate method in the automated process in which 
multi-sample processing is the precondition. In addition, this method uses the 
reagent of cyanide compound which is a poisonous substance and requires 
waste processing; thus it can hardly be called an environmentally favourable 
method. At present, this method cannot be said suitable for a fully automated 
instrument which is required to handle a large amount of waste. 
The Oxyhaemoglobin method, on the other hand, is faster in haemoglobin 
conversion rate; in fact, blood haemoglobin is converted instantaneously into 
oxyhaemoglobin. Also, it does not contain poisonous substance as 
Cyanmethaemoglobin method, making this method suitable for automation. This 
method, however, is unable to convert methaemoglobin into oxyhaemoglobin. 
Consequently, when a great amount of methaemoglobin is contained as in 
control blood, lower than real values result, although usual human blood poses 
no problems. 
Non-cyanide haemoglobin analysis method utilizes the advantages of both 
of the above methods. Non-cyanide haemoglobin analysis method rapidly 
converts blood haemoglobin as the oxyhaemoglobin method and contains no 
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poisonous substance, making it suitable for automated method. Being capable of 
analyzing methaemoglobin, this method, can accurately analyze control blood 
etc. which contain methaemoglobin.   
Figure 5. WBC & Haemoglobin Estimation 
 
This instrument analyzes the following parameters using three detector 
blocks and two kinds of reagents: 
1. Total WBC count in 1 µL of blood 
2. LYM % : Ratio of lymphocytes to whole blood 
3. MXD %: Ratio of summation of basophils, eosinophils and monocytes to 
whole WBC. 
4. NEUT % : Ratio of neutrophils to whole WBC 
5. LYM # : Absolute count of small cells in 1 µL of blood 
6. MXD # : Absolute count of middle cells in 1 µL of blood 
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7. NEUT # : Absolute count of large cells in 1 µL of blood 
8. RBC count in 1 dL of whole blood 
9. HGB : Volume of haemoglobin in 1 dL of whole blood 
10. HCT : Ratio of whole RBC volume in whole blood 
11. MCV :Mean RBC volume, which is calculated by Hct/RBC  
12. MCH : Mean Hb volume per RBC, which is calculated by Hb/RBC   
13.  MCHC : Mean RBC haemoglobin concentration, which is calculated by 
Hb/Hct 
14.  RDW – CV : RBC distribution width (%) calculated from the points 
defining 68.26% of the entire area spreading from the peak of the RBC 
particle distribution curve 
15. RDW – SD: The distribution width (fL) at the height of 20% from the 
bottom when the peak RBC particle distribution curve is taken as 100% 
16.  PLT : Platelet count in 1 µL of blood PDW : The distribution width (fL) at 
the height of 20% from the bottom with the peak of  platelet particle 
distribution curve  
17.  MPV : Mean platelet volume 
18. P–LCR: Ratio of large platelet volume exceeding 12 fL to the platelet 
volume.  
Histograms of WBC, RBC and Platelets can be calculated within the 
ranges given below: 
• WBC : Approx. 30 -300 fL (particle after lyse dripping) 
• RBC :Approx. 25 – 250 fL 
• PLT : Approx. 2 – 30 fL.  
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Display range  
• WBC            0.0 -299.9 X 103 µL 
• RBC             0.00 – 19.99 X 106 µL  
• Hb                0 – 25.0 g/dL 
• Platelets        0 – 1999 X 103 µL 
Reagent 
• Diluent : CELLPACK 
• WBC/HGB lyse reagent : STROMATOLYSER-WH 
• Detergent : CELLCLEAN 
The Sysmex KX-21 has two quality control methods. 
1) In X control, control blood is analyzed twice and the mean of the two is 
used to evaluate analyzer performance 
2) The Levy – Jennings control uses the data from a single control blood 
analysis to evaluate analyzer performance. 
PRINCIPLE OF IRON & TIBC ESTIMATION 
Iron, bound to transferrin, is released in an acidic medium and the ferric 
ions are reduced to ferrous ions. The Fe(II) ions react with Ferrozine to form a 
violet coloured complex. Intensity of the complex formed is directly proportional 
to the amount of iron present in the sample. 
For TIBC, the serum is treated with excess of  Fe(II) to saturate the iron 
binding sites on transferrin. The excess Fe(II) is adsorbed and precipitated and 
the Iron content in the supernatant is measured  by spectrophotometry to give 
the TIBC. 
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                  Acidic medium   
Fe(III)                                         Fe (II)    
                                                    
Fe (II) + Ferrozine                         Violet coloured complex  
 
REFERENCE  RANGE 
 
RBC Count                                                             4.50 – 5.90 million /mm3 (men)* 
RBCCount                                                              4.00– 5.20 million /mm3 
(women)* 
Haematocrit                                                           41 – 53 % (men)* 
Haematocrit                                                           36 – 46 % (women)* 
Mean Corpuscular Volume                                   80 – 100 fL* 
Mean Corpuscular Haemoglobin                          26 -34 pg* 
Mean Corpuscular Haemoglobin Concentration  31 – 37 g / dL* 
Serum Iron                                                            50 – 150 µg /dL* 
Total Iron Binding Capacity                                 250 – 370 µg / dL* 
Red Cell Distribution Width                                 39 – 46 fL # 
          *National Institute of Health, Adult Treatment Panel III, September 2002. 
 # Dacie & Lewis Practical Haematology, 10th edition, Churchill Livingstone 2006.   
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OBSERVATION AND RESULTS 
 
Newly diagnosed cases of nonhaematological malignancies admitted to 
our hospital with no prior chemo or radiotherapy or blood transfusion or cancer 
surgery were randomly enrolled. A total of 33 patients were enrolled as per the 
inclusion and exclusion criteria.  
AGE             
The mean age of the patients included in this study was 53.7 years. This 
study excluded patients aged below 19 years and above 69 years. 
The median age was 53 years and the mode was 65 years.  
 
                                   Table 4. Age Incidence  
 
Age Group No.
 
Percent
 
19-40 Yrs  3 9.1
41-50 yrs 13 39.4
51-60 yrs 6 18.2
61-69 yrs 11 33.3
Total 33 100.0
 
 
There were two peaks of age incidence (41-50 and 60-69 years) (Tab-4).  
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SEX 
Among the randomly enrolled 33 patients, 25 were women while the 
remaining 8 were men (Fig-6).  
Figure 6. 
S E X  INC IDE NC E
Male 
8 
Female 
25
 
 
TYPE OF MALIGNANCIES 
 
    Among the eight male patients, four suffered from Gastrointestinal cancer, 
two suffered from lung cancer, one had metastatic cancer in cervical lymph 
nodes with unknown primary and the remaining one was a case of Ca penis       
(Fig-7). 
Figure 7 
INCIDENCE OF MALIGNANCIES IN MEN
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Among the 25 female patients, 11 suffered from Ca Breast, six suffered from 
Gastrointestinal malignancy, three had Ca Cervix, two had Ca Oral cavity, two 
were Ovarian malignancies, and one had metastatic cancer in cervical lymph 
nodes (Fig-8).  
Figure 8 
INCIDENCE OF MALIGNANCIES IN WOMEN
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SEVERITY OF ANAEMIA 
 Mild anaemia (Hb 10 – 12 g /dL) was present in 22 cases, moderate 
anaemia (Hb 8 – 9.9 g/dL) in 8 cases and severe anaemia (Hb <8 g/dL) in               
3 cases (Fig-9).                                  
Figure 9 
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PERIPHERAL SMEAR STUDY 
Out of the 33 peripheral smears studied, 70% (n=23) were normocytic 
normochromic (Fig 12, 13, 16 & 17), 21% (n= 7) were microcytic hypochromic              
(Fig 11, 15 & 18) and the remaining 9% (n=3) were normocytic hypochromic             
(Fig 14). No fragmented red cells or microspherocytes were noted in any of the 
smears (Fig-10).  
Figure 10 
PERIPHERAL SMEAR
23
7
3 Normocytic
Normochromic
Microcytic Hypochromic
Normocytic
Hypochromic
 
All patients had their Total and Differential WBC counts and Platelet 
counts checked and their Peripheral Smears examined. No evidence of Bone 
Marrow suppression or replacement was found. 
  All the 33 patients had normal liver and kidney function tests. 
 
THE HAEMATOLOGICAL PARAMETERS OBSERVED 
• No of patients with Hb <12 g/dL        - 33 
• RBC count                                        - 3.83 million / μL 
• Haemoglobin                                    - 10.7 g/dL 
• Haematocrit                                      - 34.4% 
• MCV                                                -  84.9 fL 
• MCH                                                -  25.5 pg 
• MCHC                                             -  30.7 g/dL 
Data are shown as Median. 
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RBC COUNT IN MEN 
Seven out of eight men (87.5%) had reduced RBC count (Tab-5) 
                                               
Table 5. RBC Count in Men 
 
RBC 
million/μL No. Percent
< 4.5 7 87.5
4.5-5.9* 1 12.5
Total 8 100.0
 
                                                     *Normal range, National Institute of Health, 
USA,    Adult Treatment Panel III, September 2002 
 
RBC COUNT IN WOMEN 
Fifteen women (60%) had reduced RBC counts in the present study (Tab-6). 
 
Table 6.  RBC Count in Women 
 
RBC 
million/μL No. Percent
< 4 15 60.0
4 – 5.2* 10 40.0
Total 25 100.0
 
HAEMATOCRIT IN MEN 
All the men in the present study had reduced haematocrit (Tab-7).                       
                                      
Table 7.  Haematocrit in Men 
 
HCT %* No. Percent
< 40 8 100.0
 
                                                                                *Normal range (41.0 – 53.0%)  
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HAEMATOCRIT IN WOMEN 
Twenty women (80%) had reduced haematocrit (Tab-8). 
 
Table 8.  Haematocrit in Women 
 
HCT % No. Percent
< 36 20 80.0
36 – 46* 5 20.0
Total 25 100.0
 
 
 
MEAN CORPUSCULAR VOLUME 
Reduced MCV was observed in 10 patients (30.3%) out of 33 cases (Tab-9). 
                      
Table 9.  Mean Corpuscular Volume 
 
MCV fL No. Percent
< 80 10 30.3
80 – 100* 23 69.7
Total 33 100.0
 
                          
MEAN CORPUSCULAR HAEMOGLOBIN 
Seventeen patients (51.5%) had reduced MCH in the present study (Tab-10).                
Table 10.  Mean Corpuscular Haemoglobin 
 
MCH pg No. Percent
<26 17 51.5
26 – 34* 16 48.5
Total 33 100.0
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MEAN CORPUSCULAR HAEMOGLOBIN CONCENTRATION 
 
Eighteen patients (54.5%) had reduced MCHC in the present study (Tab-11). 
 
Table 11.   Mean Corpuscular Haemoglobin Concentration 
 
MCHC 
g/dL No. Percent
< 31 18 54.5
31 – 37* 15 45.5
Total 33 100.0
 
                          
 
RED CELL DISTRIBUTION WIDTH 
Fifteen patients (45.5%) had increased RDW in the present study (Tab-12). 
 
Table 12.   Red Cell Distribution Width 
 
RDW fL  No. Percent
39 – 46# 18 54.5
> 46 15 45.5
Total 33 100.0
                                                                                                     # Dacie & Lewis13      
 
SERUM IRON  
In the present study, ten patients (30%) had serum iron <50 μg/dL (Tab-13). 
 
Table 13. Serum Iron 
Serum 
Iron μg/dL No. Percent
< 50 10 30
50-150* 23 70
Total 33 100.0
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SERUM FERRITIN  
 
In the present study, 16 patients (48.5%) had serum ferritin >50 ng/mL,      
13 patients (39.4%) had serum ferritin between 12–50 ng/mL and the remaining 
four patients (12.1%) had <12 ng/mL of ferritin (Tab-14). 
Table 14.  Serum Ferritin Levels 
 
Serum ferritin 
ng/mL ¥ No. Percent
<12 4 12.1
12-50 13 39.4
>50 16 48.5
Total 33 100.0
 
¥ Wintrobe’s Clinical Haematology61 . 
 
 
TOTAL IRON BINDING CAPACITY 
 
TIBC was within normal range in 18 patients (54.55%), low in 11 patients 
(33.33%), and raised in four patients (12.12%) in the present study (Tab-15). 
 
Table 15.  Total Iron Binding Capacity 
 
TIBC μg/dL No. Percent
< 250 11 33.33
250 – 370* 18 54.55
> 370 04 12.12
Total 33 100.0
 
 
* Normal range 
National Institute of Health, USA, 
Adult Treatment Panel III, Sep 2002. 
 
 49
AGEWISE STATISTICAL ANALYSIS 
Mean Haemoglobin levels varied significantly based on age. When 
ANOVA test was conducted (F=3.246; P<0.05) the mean Hb level was highest in 
the age group of 41 – 50 years (10.78 g/dL) and lowest in the age group of                
61– 69 years (9.04 g/dL) (Tab–16).                                                    
Table-16.Agewise Distribution of Haemoglobin 
 
 
Age  
Hb(g/dL) 
Mean S.D No.
19-40 Yrs  10.73 .55 3
41-50 yrs 10.78 .97 13
51-60 yrs 10.20 1.10 6
61-69 yrs 9.04 2.02 11
TOTAL 10.09 1.56 33
 
  
Mean RBC count varied significantly based on age .When ANOVA test 
was conducted (F=3.089; P<0.05) the mean RBC count was highest in the age 
group of 19-40 years (4.42 million/mm3) and lowest in the age group of                          
61–69 years (3.59 million/mm3) (Table-17).                          .         
Table-17. Agewise Distribution of RBC count (million/mm3) 
 
Age 
 
RBC count 
Mean S.D No.
19-40 Yrs  4.42 .74 3
41-50 yrs 4.10 .53 13
51-60 yrs 3.78 .43 6
61-69 yrs 3.59 .50 11
TOTAL 3.90 .57 33
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Mean haematocrit varied significantly based on age .When ANOVA test 
was conducted (F=5.566; P<0.01) the mean haematocrit was highest in the age 
group of 19- 40 years (36.10%) and lowest in the age group of 61–69 years 
(29.59%) (Table-18). 
Table-18. Agewise Distribution of Haematocrit 
 
Age 
 
HCT(%) 
Mean S.D No.
19-40 Yrs  36.10 .56 3
41-50 yrs 34.78 2.17 13
51-60 yrs 32.50 3.26 6
61-69 yrs 29.59 4.82 11
TOTAL 32.75 4.11 33
 
Mean MCV did not vary significantly based on age .When ANOVA test 
was conducted (F=0.346; P>0.05) the mean MCV was highest in the age group 
of 51- 60 years (86.18fL) and lowest in the age group of 61– 69 years (82.86fL) 
(Table-19). 
Table-19. Agewise Distribution of Mean Corpuscular Volume 
 
Age 
 
MCV(fL) 
Mean S.D No.
19-40 Yrs  83.03 12.41 3
41-50 yrs 86.07 7.87 13
51-60 yrs 86.18 6.79 6
61-69 yrs 82.86 10.16 11
TOTAL 84.75 8.65 33
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Mean MCH did not vary significantly based on age .When ANOVA test 
was conducted (F=1.614; P>0.05) the mean MCH was highest in the age group 
of 51 - 60 years (27.08 pg) and lowest in the age group of 19 - 40 years                      
(22.60 pg) (Table-20). 
Table-20. Agewise Distribution of Mean Corpuscular Haemoglobin 
 
Age 
 
MCH(pg) 
Mean S.D No.
19-40 Yrs  22.60 1.92 3
41-50 yrs 26.90 3.27 13
51-60 yrs 27.08 2.88 6
61-69 yrs 25.20 4.22 11
TOTAL 25.98 3.60 33
 
 
Mean MCHC did not vary significantly based on age. When ANOVA test 
was conducted (F=1.559; P>0.05) the mean MCHC was highest in the age group 
of 51 - 60 years (31.38 g/dL) and lowest in the age group of 19 - 40 years                          
(29.73 g/dL) (Table-21). 
Table-21. Agewise Distribution of Mean Corpuscular Haemoglobin 
Concentration 
 
 
 
Age 
MCHC(g/dL) 
Mean S.D No.
19-40 Yrs  29.73 1.05 3
41-50 yrs 31.26 1.17 13
51-60 yrs 31.38 1.10 6
61-69 yrs 30.27 2.13 11
TOTAL 30.82 1.59 33
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Mean RDW did not vary significantly based on age. When ANOVA test 
was conducted (F=1.560; P>0.05) the mean RDW was highest in the age group 
of 61- 69 years (53.23fL) and lowest in the age group of 41 - 50 years (46.25fL) 
(Table-22).     
Table-22. Agewise Distribution of Red cell Distribution Width 
 
 
Age 
RDW(fL) 
Mean S.D No.
19-40 Yrs  46.87 2.74 3
41-50 yrs 46.25 5.55 13
51-60 yrs 47.48 3.31 6
61-69 yrs 53.23 12.47 11
TOTAL 48.85 8.51 33
 
 
Mean Iron levels did not vary significantly based on age. When ANOVA 
test was conducted (F=1.067; P>0.05) the mean serum iron level was highest in 
the age group of 51- 60 years (73.02 μg/dL) and lowest in the age group of 19-40 
years (40.75 μg/dL) (Table-23).           
Table-23. Age wise Distribution of Serum Iron (μg/dL) 
 
Age 
Serum Iron 
Mean S.D No.
19-40 Yrs  40.75 16.01 3
41-50 yrs 64.97 36.77 13
51-60 yrs 73.02 42.06 6
61-69 yrs 52.24 16.19 11
TOTAL 59.99 31.28 33
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Mean TIBC did not vary significantly based on age. When ANOVA test 
was conducted (F=0.292; P>0.05) the mean TIBC was highest in the age group 
of 51- 60 years (304.32 μg/dL) and lowest in the age group of 41-50 years 
(274.30 μg/dL) (Table-24).         
Table-24. Agewise Distribution of TIBC (μg/dL) 
 
Age 
TIBC 
Mean S.D No.
19-40 Yrs  288.00 69.20 3
41-50 yrs 274.30 45.00 13
51-60 yrs 304.32 89.62 6
61-69 yrs 285.59 70.87 11
TOTAL 284.77 63.25 33
  
 
Mean Ferritin levels did not vary significantly based on age. When ANOVA 
test was conducted (F=0.051; P>0.05) the mean ferritin was highest in the age 
group of 61- 69 years (97.49 ng/mL) and lowest in the age group of 41-50 years 
(81.59 ng/mL) (Tab-25).           
                         Table-25. Agewise Distribution of Serum Ferritin (ng/mL) 
 
Age 
 
Ferritin 
Mean S.D No.
19-40 Yrs  93.93 59.41 3
41-50 yrs 81.59 59.81 13
51-60 yrs 88.68 61.86 6
61-69 yrs 97.49 152.28 11
TOTAL 89.30 97.24 33
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GENDERWISE STATISTICAL ANALYSIS 
 
Mean Haemoglobin levels did not vary significantly between men and 
women. When t-test was applied (t=1.232; P>0.05)) the average Hb in men was 
9.50 g/dL whereas for women it was 10.28 g/dL  (Tab–26). 
Table-26. Distribution of Haemoglobin in both sexes 
 
 
Sex 
Hb(g/dL) 
Mean S.D No.
Male 9.50 1.67 8
Female 10.28 1.51 25
TOTAL 10.09 1.56 33
 
 
Mean RBC count did not vary significantly between men and women. 
When t-test was applied (t=0.075; P>0.05)) the average RBC count in men was 
3.89 million/mm3 whereas for women it was 3.91 million/mm3  (Tab-27). 
 
Table-27. Distribution of RBC count(million/mm3) in both sexes 
 
 
 
Sex 
RBC count 
Mean S.D No.
Male 3.89 .72 8
Female 3.91 .53 25
TOTAL 3.90 .57 33
 
 
 
 
 
 55
Mean Haematocrit did not vary significantly between men and women. 
When t-test was applied (t=1.463; P>0.05)) the average HCT in men was 30.94%  
whereas for women it was 33.34%   (Tab-28). 
Table-28. Distribution of Haematocrit(%) in both sexes 
 
 
Sex 
 
HCT 
Mean S.D No.
Male 30.94 4.25 8
Female 33.34 3.97 25
TOTAL 32.75 4.11 33
 
 
Mean MCV did not vary significantly between men and women. When t-
test was applied (t=1.625; P>0.05)) the average MCV in men was 80.53fL  
whereas for women it was 86.10fL   (Tab-29). 
 
Table-29. Distribution of MCV in both sexes 
 
 
Sex 
 
MCV(fL) 
Mean S.D No.
Male 80.53 9.83 8
Female 86.10 7.99 25
TOTAL 84.75 8.65 33
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Mean MCH did not vary significantly between men and women. When t-
test was applied (t=1.147; P>0.05) the average MCH in men was 24.71 pg  
whereas for women it was 26.38 pg   (Tab-30). 
Table-30. Distribution of MCH in both sexes 
 
 
 
Sex 
MCH(pg) 
Mean S.D No.
Male 24.71 4.06 8
Female 26.38 3.43 25
TOTAL 25.98 3.60 33
 
 
Mean MCHC did not vary significantly between men and women. When         
t-test was applied (t=0.535; P>0.05) the average MCHC in men was 30.55 g/dL  
whereas for women it was 30.90 g/dL   (Tab-31). 
 
Table-31. Distribution of MCHC in both sexes 
 
 
 
Sex 
MCHC(g/dL) 
Mean S.D No.
Male 30.55 1.85 8
Female 30.90 1.54 25
TOTAL 30.82 1.59 33
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Mean RDW did not vary significantly between men and women. When                      
t-test was applied (t=1.440; P>0.05) the average RDW in men was 52.56 fL 
whereas for women it was 47.67 fL   (Tab-32). 
 
Table-32. Distribution of RDW in both sexes 
 
 
Sex 
RDW(fL) 
Mean S.D No.
Male 52.56 11.34 8
Female 47.67 7.28 25
TOTAL 48.85 8.51 33
 
 
 
Mean serum iron levels did not vary significantly between men and 
women. When t-test was applied (t=1.428; P>0.05) the average serum iron in 
men was 46.46 μg/dL  whereas for women it was 64.32 μg/dL   (Tab -33 ). 
  
Table-33. Distribution of serum iron (μg/dL) in both sexes 
 
 
Sex 
 
Serum Iron 
Mean S.D No.
Male 46.46 14.61 8
Female 64.32 34.09 25
TOTAL 59.99 31.28 33
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Mean TIBC did not vary significantly between men and women. When                     
t-test was applied (t=1.134; P>0.05) the average TIBC in men was 306.75 μg/dL 
whereas for women it was 277.73 μg/dL   (Tab-34). 
 
 
Table-34. Distribution of TIBC in both sexes 
 
 
Sex 
TIBC(μg/dL) 
Mean S.D No.
Male 306.75 70.63 8
Female 277.73 60.55 25
TOTAL 284.77 63.25 33
 
 
 
 
Mean Ferritin did not vary significantly between men and women. When                           
t-test was applied (t=0.725; P>0.05) the average ferritin in men was 67.45 ng/mL 
whereas for women it was 96.29 ng/mL   (Tab-35). 
 
Table-35. Distribution of serum ferritin in both sexes 
 
 
Sex 
 
Ferritin (ng/mL) 
Mean S.D No.
Male 67.45 67.52 8
Female 96.29 105.20 25
TOTAL 89.30 97.24 33
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DISCUSSION 
AGE INCIDENCE 
In the Australian Cancer Anaemia Survey, the median age of the 
participants was 60 years (Table-36). The median age of patients in the present 
study was 53 years. This could be explained by two factors. Firstly, the present 
study consists of an overwhelming proportion of female patients (72.5%) who 
have an early peak of cancer incidence. Secondly, the present study excluded 
patients older than 69 years.  
Table – 36. Age Incidence 
S No Study Median Mean Range 
1 ACAS 60 59.7 19-90 
2 POLCAS 56 54.8 >=18 
3 ECAS - 59.0 18-96 
4 Present Study 53 53.7 19-69 
 
In the present study, the mode was 65 years of age. This correlates with 
the statistics compiled from the National Cancer Institute Surveillance, 
Epidemiology, and End Results (SEER) program which indicate the incidence of 
cancer among individuals >= 65 years of age is 2,261.0 per 100,000 as 
compared with only 207.3 per 100,000 for those 65 years62.  
Marimuthu P, NIMHANS, Bangalore, in his projection of cancer incidence 
in five major Indian cities for the year 2008 (Fig-1), has stated that males from 
Chennai would have an increasing trend from the age of 50 to 69 years and 
females from Chennai might have more number of cases from 45 to 65 years of 
age63. 
In the present study, there are two peaks in age incidence (41-50 and 60-
69). This may be due to the fact that women constitute the majority (75.8%) of 
the study population and it correlates with the age incidence for women in five 
major Indian cities (Fig-2)  projected by Marimuthu P63           
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SEX INCIDENCE  
In the Australian Cancer Anaemia Survey, 61.2% of the patients were 
women. In ECAS women accounted for 56.4% of the study group.The Indian 
Council of Medical Research’s  population-based cancer registry data of 1982-84 
shows that the total number of incident cases in males were 0.29 million and in 
females the incident cases of cancer were 0.32 million. The present study, with 
randomly selected patients has 72.5% of women reflecting the general trend of 
female preponderance. 
INCIDENCE OF MALIGNANCY OF VARIOUS ORGANS  
The distribution of cancer types varies from country to country, and 
differences are most marked between developed and developing countries. For 
example, among men in developed countries prostate cancer is the second most 
common cancer and colorectal cancer the third most common cancer. Among 
men in developing countries, however, gastric cancer and liver cancer are the 
second and third most common cancers, after lung cancer. Among women, 
breast cancer is the most common cancer in developed and developing 
countries, but cervical cancer is the second most common cancer in developing 
countries, whereas colorectal, lung, stomach, and endometrial cancers exceed 
cervical cancer cases in developed countries64. 
In our department oral, ENT, oesophagus, gastrointestinal tract, skin, 
penis and liver were the most common malignancies among male patients in 
2008. The small sample of the present study roughly reflects the incidence of our 
department. 
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Among female patients, carcinoma cervix, breast, oral, ENT, oesophagus, 
stomach, and ovary were the most common malignancies in our department in 
2008. The present study generally reflects the same trend. 
In POLCAS breast cancer patients accounted for 21.49% of the study 
population. In ECAS 21.8% and in ACAS 26.8% had breast cancer. In the 
present study, breast cancer accounted for 30.3% of the study population. 
SEVERITY OF ANAEMIA 
In the European Cancer Anaemia Survey (ECAS), anaemia was 
categorized as mild (Hb 10 -11.9 g/dL), moderate ( Hb 8 – 9.9 g/dL) or severe  
(Hb < 8 g/dL) based on the Common Toxicity Criteria, National Cancer Institute, 
USA and the European Organization for Research and Treatment of Cancer 
(EORTC). In ECAS study, among anaemic patients, 8.9% had severe anaemia, 
49.2% had moderate and 41.9% had mild anaemia.   
In the Australian Cancer Anaemia Survey (ACAS), 78% of the anaemic 
patients had mild anaemia (Hb 10 -11.9 g/dL) at enrolment (Table – 37). 
In the present study, among anaemic patients, 66.67% had mild anaemia, 
24.24% had moderate and another 9.09% had severe anaemia. The pattern of 
severe degree of anaemia generally reflects that of the Europe. Proportion of 
patients with moderately severe anaemia was a little less when compared to 
ECAS. 
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Table – 37. Severity Of Anaemia 
S.No Series Mild Moderate Severe 
1 ECAS 41.9 49.2 8.9 
2 ACAS 78 22 
3 POLCAS 82.1 16.2 1.7 
4 Present Study 66.67 24.24 9.09 
 
Out of the 11 patients with carcinoma of breast, 10 had mild anaemia and 
the remaining patient had moderate degree of anaemia.  
HAEMATOLOGICAL PARAMETERS               
 In the present study, the median values of MCV (84.9) and MCHC (30.7) 
obtained were lower than those obtained in European cancer patients (Table – 
38). But the median values of the RBC count (3.83 million / μL ), haemoglobin 
(10.7 g/dL)  and Haematocrit (34.4%) were higher. This may be due the highly 
prevalent iron deficiency in Indian women (the present study has more female 
patients), the different case mix and age restriction of the present study, 
undetected haemoglobinopathies etc. contributing to the variation in the 
haematological parameters in the present study. 
Table – 38. Haematological Parameters 
S.No Parameter # ECAS* Present Study 
1 RBC (106 / μL ) 3.3 3.83 
2 Hb (g/dL ) 9.6 10.7 
3 HCT ( % ) 29.6 34.4 
4 MCV ( fL ) 89 84.9 
5 MCHC ( g/dL ) 33 30.7 
 
* The European Cancer Anaemia Survey 
     # Data are given as median 
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CORRELATION OF HAEMATOLOGICAL PARAMETERS 
In the present study, mean Hb, RBC count, Haematocrit, MCV, MCH and 
MCHC were lower in men and these values varied more widely in men. Mean 
RDW was higher in men and RDW varied more widely in men. Mean serum iron 
and mean serum ferritin were higher in women and mean TIBC was lower in 
women. These findings indicate that iron deficiency predominates over other 
factors in the causation of anaemia in male cancer patients in the present study. 
Mean Haemoglobin, RBC count, Haematocrit, and MCV were the lowest 
in above 60 years age group. Mean RDW was the highest in above 60 years age 
group. 
Mean MCH, MCHC and mean serum iron were the lowest in 40 years or 
below age group.  
In the present study, 12 patients had both reduced MCH and reduced 
MCHC. Among them only six patients had reduced serum iron. This is explained 
by the fact that the red cell indices are mainly helpful in detecting mild or early 
red cell abnormalities. In severe anaemias, peripheral blood smear is sufficiently 
characteristic and red cell indices do not provide additional information.  
 In the present study, 17 patients had serum ferritin levels <50 ng/mL. 
Among them eight patients had both MCH and MCHC reduced, six patients had 
either MCH or MCHC reduced and the remaining three had both MCH and 
MCHC in the normal range. 
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In the present study of cancer patients with anaemia, RBC counts were 
within  the normal range in 11 patients. The red cell count can be in the normal 
range in people who are anaemic on the basis of the haemoglobin level when the 
red cells are microcytic, as in thalassemia minor or iron deficiency11.  
In the present study, six patients had reduced MCV and increased RDW 
indicating iron deficiency. Among these patients three had serum ferritin levels 
less than 12 ng/mL, two had serum ferritin between 12 and 50 ng/mL  and one 
patient had  ferritin level more than 50 ng/mL.  
Haematocrit was within normal range in five women in the present study. 
All of them had mild anaemia, normal red cell count and normal serum iron. 
Among them, in only one patient, MCV, MCH and MCHC were within the normal 
range. The others had atleast one parameter reduced. This again proves the 
utility of red cell parameters as indicators of early or mild red cell change. 
CORRELATION OF PERIPHERAL SMEAR WITH OTHER PARAMETERS 
In the present study, out of the seven microcytic hypochromic peripheral 
smears, six were accounted for by Carcinoma of oesophagus and stomach and 
the remaining one by Carcinoma of breast. 
In the present study, out of the eleven cases of carcinoma of breast, nine 
had normocytic normochromic, one had normocytic hypochromic and the other 
had microcytic hypochromic peripheral smears. 
In the present study, ten patients had reduced MCV while seven of them 
had microcytic hypochromic peripheral smears. Other smears also had 
microcytes in varying proportions.  
 66
In the present study 17 patients had reduced MCH, Among them, only 
seven peripheral smears were microcytic hypochromic and three others were 
normocytic hypochromic. The remaining seven smears were predominantly 
normocytic normochromic but also had hypochromic microcytes in varying 
proportions. This proves that red cell indices are mainly helpful in detecting mild 
or early red cell abnormalities and peripheral smear is sufficiently characteristic in 
severe anaemias. 
The peripheral smear picture correlated well with serum ferritin levels in 
the present study. Four patients had serum ferritin levels < 12 ng/mL, all of them 
had microcytic hypochromic peripheral smear. 
In the present study, 17 patients had serum ferritin < 50 ng / mL indicating 
most probable iron deficiency. Among them, 11 patients had normocytic 
normochromic, five  had microcytic hypochromic and the remaining one had 
normocytic hypochromic peripheral smears. 
Out of the three patients with Hb <8g/dL, two had microcytic hypochromic 
smears while the other had mainly normocytic normochromic picture with many 
microcytes.  
Out of the seven patients with microcytic hypochromic peripheral smears, 
only two had reduced serum iron levels.The remaining five patients had serum 
iron levels between 50 and 70/ μg/dL. 
DIFFERENTIAL DIAGNOSIS 
A number of different factors can contribute to the development of 
anaemia in malignancy, and it is common for several factors to operate in 
patients with malignancy. The type of anaemia depends on the dominant 
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underlying mechanism or mechanisms, and the most important are blood loss, 
chronic inflammatory-like response, infection, inadequate nutrition, bone marrow 
suppression, impaired renal function, and haemolysis.  
In the present study, all the patients had normal renal function tests. No 
evidence of bone marrow suppression or haemolysis was observed in any of the 
patients. History, Clinical examination, Complete Blood Count and other 
investigations did not reveal infection in any patient studied except only one 
(patient ID: 35671). She had carcinoma of breast with skin ulceration and 
infection. 
Much of the anaemia commonly observed in patients with cancer can be 
attributed to the mechanisms involved in the anaemia of chronic disease. The 
main differential diagnosis is iron deficiency anaemia61. 
Table – 39. Serum Values To Differentiate Anaemia Of Chronic Disease 
From Iron Deficiency Anaemia 
Test Anaemia of 
chronic disease 
Iron deficiency 
anaemia 
Both 
Iron 
  
Transferrin(TIBC)            
Ferritin 
 
In the present study, only four patients had raised TIBC (>370μg/dL). 
Among them, three had reduced serum ferritin (<50 ng/mL) indicating depletion 
of body iron stores while the remaining one had raised serum ferritin. 
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In the present study, out of the 11 cases with reduced TIBC, all had serum 
ferritin above 12 ng/mL. Seven patients had reduced serum iron, reduced TIBC 
and normal serum ferritin indicating that anaemia of chronic disease was a 
significant contributing factor in the development of anaemia in them (Table-39). 
Out of the ten patients with reduced serum iron levels, six had reduced 
serum ferritin levels (<50 ng/dL) three had normal and the remaining one had 
elevated serum ferritin levels. This is explained by the fact that low serum iron 
concentrations are found in iron deficiency anaemia, anaemia of chronic disease, 
and during the acute-phase response, including after surgery. Therefore, low 
serum iron concentrations do not necessarily indicate an absence of storage 
iron13. 
Out of the 17 patients with reduced serum ferritin (<50 ng/mL), only six 
patients had reduced serum iron levels. This is explained by the fact that serum 
iron level falls after the iron stores are depleted and other factors also contribute 
to the development of anaemia in these cancer patients with normal serum iron.            
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SUMMARY AND CONCLUSION 
• In the present study, the mode of age incidence was 65 years. The 
median age was 53 years and the mean was 53.7 years. 
• Out of the 33 patients studied, 72.5% were women. Breast cancer 
accounted for 30.3% of the total cases studied. 
•  Mild anaemia was observed in 66.67% of the patients while 24.24% had 
moderate and 9.09% had severe anaemia. 
• The following median values were obtained: RBC count –                          
3.83 million/mm3, Haemoglobin – 10.7 g/dL, Haematocrit – 34.4%,                  
MCV – 84.9 fL, and MCHC – 30.7 g/dL. 
• Mean Hb, RBC count, Haematocrit, MCV, MCH and MCHC were lower in 
men. Mean RDW was higher in men. 
• Mean serum iron and mean serum ferritin were higher in women and 
mean TIBC was lower in women.  
• Out of the 11 cases with reduced TIBC, all had serum ferritin above                  
12 ng/mL. Seven patients had reduced serum iron, reduced TIBC and 
normal serum ferritin indicating that anaemia of chronic disease was a 
significant contributing factor in the development of anaemia in them. 
• Twelve patients had both MCH and MCHC reduced. Among them only six 
patients had reduced serum iron proving that red cell parameters are 
indicators of early or mild red cell change. 
• In the present study of cancer patients with anaemia, RBC counts were 
normal in 33% of patients (occurs in iron deficiency anaemia and 
thalassaemia syndromes). 
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• 18% of patients had reduced MCV and increased RDW (occurs in iron 
deficiency). 
Anaemia was consistently observed in nonhaematological malignancies in all 
age groups. Normocytic normochromic anaemia was most commonly seen. Red 
cell indices and serum iron, TIBC and serum ferritin were found to be useful 
parameters in precise assessment of anaemia and its type. Bone marrow 
suppression, haemolysis and abnormal renal / liver functions were not observed. 
This study proves that a number of different factors contribute to the 
development of anaemia in malignancy, and it is common for several factors to 
operate in patients with malignancy. The type of anaemia depends on the 
dominant underlying mechanism or mechanisms. 
In view of the potential benefits of treating anaemia, it is hoped that 
comprehensive management of anaemia in malignancies will receive more 
attention in the future. 
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S 
No IP No Age Sex Hb TC Platelets
RBC  
count HCT MCV MCH MCHC RDW
Serum 
Iron TIBC Ferritin
Transferrin 
Saturation Peripheral Smear
History in 
Clinical Exam
Renal 
Function 
Tests
Liver 
Function 
Tests
1 35809 64 F 7.2 6000 169000 2.54 24.5 96.5 28.3 29.4 58 23 230 44.08 10 NN Ca Lip Normal Normal
2 34298 65 M 8.2 5400 232000 3.28 26.3 80.2 25 31.2 73.7 40 245 32.7 16.33 NN Met Adeno Ca Normal Normal
3 35671 65 F 9.4 29400 309000 3.09 30.6 99 30.4 30.7 71.8 28.12 150 513.7 18.75 NN Ca Breast Normal Normal
4 34317 38 M 11.3 3500 152000 5.21 36.7 70.4 21.7 30.8 47.4 26.94 210 143.3 12.83 MH Ca Oesophagus Normal Normal
5 34750 65 M 6.5 6400 465000 3.4 24.3 71.5 19.1 26.7 59.5 56 430 11.2 MH Ca Oesophagus Normal Normal
6 29195 53 M 11 12800 517000 4.42 34.9 79 24.9 31.5 46 62 380 17.7 NN Adeno Ca Bronchus Normal Normal
7 18211 69 F 8 5600 296000 3.81 26.9 70.6 21 29.7 51.4 67 320 5.7 MH Ca Oesophagus Normal Normal
8 18008 45 F 8.5 4800 335000 4.71 32.7 74.7 21.5 30 55.1 68 330 26.7 MH Ca Oesophagus Normal Normal
9 17030 50 F 11.3 9400 551000 3.85 35.6 92.5 29.4 31.7 53 180 220 146.8 NN Ca Breast Normal Normal
10 17256 56 F 8.2 9400 472000 3.25 26.1 80.3 25.2 31.4 49.9 123 380 149.5 NN Met sq cell Ca Normal Normal
11 12093 47 M 10.3 14000 552000 4.41 32.9 74.6 23.4 31.3 40.2 59 300 163.2 NN Ca Lung Normal Normal
12 7696 65 F 6.3 8100 536000 3.36 23.3 69.3 18.8 27 41.5 69 320 2.7 MH Ca Stomach Normal Normal
13 205333 45 F 11.2 9100 249000 4.64 36.7 79.1 24.1 30.5 57.9 62.46 281 42.71 22.2 NH Ca Cervix Normal Normal
14 41192 44 F 11.3 9600 610000 3.72 34.4 92.5 30.4 32.8 47.5 50.41 313.8 17.37 16.06 NN Ca Cheek Normal Normal
15 40746 45 F 10.8 8600 313000 4.12 35.5 86.2 26.2 30.4 44.8 37 231 200.2 16.02 NN Ca Breast Normal Normal
16 40745 53 F 11.1 5400 332000 3.79 34.5 91 29.3 32.2 43.3 125.38 378.9 33.49 33.09 NN Ca Breast Normal Normal
17 43130 50 F 11.1 10500 351000 4.65 37.4 80.4 23.9 29.7 41.8 55.7 338.7 65.58 16.45 NH Ca Breast Normal Normal
18 42982 28 F 10.7 5500 364000 4.31 36 83.5 24.8 29.7 43.9 58.3 342 110.5 17.05 NH Ca Ovary Normal Normal
19 37921 60 F 10.2 5700 401000 4.07 33.9 83.3 25.1 30.1 52.5 22 182 146 12.09 NN Ca Ovary Ascites Normal Normal
20 7675 65 F 10.4 4700 262000 4.08 33.9 83.1 25.5 30.7 42.1 57 286 23.7 NN Ca Oesophagus Normal Normal
MASTER CHART
S 
No IP No Age Sex Hb TC Platelets
RBC  
count HCT MCV MCH MCHC RDW
Serum 
Iron TIBC Ferritin
Transferrin 
Saturation Peripheral Smear
History in 
Clinical Exam
Renal 
Function 
Tests
Liver 
Function 
Tests
21 9605 50 F 10.7 9200 366000 3.83 34.8 90.9 27.9 30.7 42.9 51 284 42.6 NN Ca Breast Normal Normal
22 8201 50 F 11 7600 283000 3.84 35.4 92.2 28.6 31.1 44.8 57 265 47.6 NN Ca Rectum Normal Normal
23 9892 66 F 11.2 4100 228000 3.85 34.3 89.1 29.1 32.7 43 61.8 290 106.7 NN Ca Breast Normal Normal
24 8203 47 F 11.4 6500 518000 3.74 34.6 92.5 30.5 32.9 43.8 71 206.4 112.8 NN Ca Rectum Normal Normal
25 11721 65 F 11.6 12300 368000 4.17 35.4 84.9 27.8 32.8 41.7 63.75 311.5 110 NN Ca Breast Normal Normal
26 9434 50 M 9.1 12700 412000 3.15 29.6 94 28.9 30.7 44.1 26 280 24.7 NN Ca Stomach Normal Normal
27 9690 55 M 10.9 7100 210000 3.42 33.1 96.8 31.9 32.9 47.7 58.75 290 137.6 NN Ca Penis Normal Normal
28 18706 40 F 10.2 11600 329000 3.74 35.6 95.2 21.3 28.7 49.3 37 312 28 NN Ca Cervix Normal Normal
29 13740 45 F 11.8 14000 442000 4.99 37.9 76 23.6 31.1 43 59 210 52.6 MH Ca Breast Normal Normal
30 15354 65 F 11.9 7800 363000 4.05 36.3 89.6 29.4 32.8 40.9 66 240 212.7 NN Ca Breast Normal Normal
31 105679 47 F 11.6 5000 229000 3.71 34.6 93.3 31.3 33.5 42.3 68 306 117.8 NN Ca Breast Normal Normal
32 15601 65 M 8.7 5400 221000 3.82 29.7 77.7 22.8 29.3 61.9 43 319 9.2 MH Ca Stomach Normal Normal
33 21406 55 F 9.8 8500 560000 3.75 32.5 86.7 26.1 30.2 45.5 47 215 47.8 NN Ca Cervix Normal Normal
